Management of Ventricular Premature Complexes with Mexiletine
Guideline Recommendations
- The American College of Cardiology recommends beta-blockers as first-line therapy for symptomatic VPCs 1
- For patients with recurrent VPCs that trigger symptoms or ventricular dysfunction, catheter ablation should be considered before antiarrhythmic medications like mexiletine 2, 1
- The European Society of Cardiology lists mexiletine as an option for ventricular tachycardia but not specifically as a preferred agent for isolated VPCs 3
Clinical Considerations
- Unlike sodium channel blockers used after myocardial infarction that increased mortality in the CAST trial, mexiletine does not prolong QT intervals, making it potentially safer in certain contexts 4
Special Populations and Contraindications
- Mexiletine should be used with caution in patients with sinus node dysfunction, severe AV conduction disturbances, severe heart failure, or reduced left ventricular ejection fraction 3
- Mexiletine is not contraindicated in patients with inherited long QT syndrome type 3 (LQT3), unlike other sodium channel blockers 3
Mexiletine for PVCs: Limited Role as Second-Line Therapy
Guideline-Based Treatment Algorithm for PVCs
- The European Society of Cardiology recommends considering catheter ablation before medications like mexiletine for recurrent PVCs triggering symptoms or ventricular dysfunction 5, 6
- Mexiletine may be considered only after beta-blockers have failed or are contraindicated, according to the European Heart Journal 7
Special Clinical Context: Acute Coronary Syndromes
- In the acute MI setting, intravenous lidocaine (mexiletine's structural analog) may be considered for recurrent VT/VF not responding to beta-blockers or amiodarone, as suggested by the European Heart Journal 7
- Prophylactic antiarrhythmic therapy is not recommended and may be harmful, as stated by the European Heart Journal 7